Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 83,925 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 2 Interventional Results available

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

NCT02396511
View directory record Official record
Conditions
Choriocarcinoma
Interventions
TRC105, Bevacizumab
Biological
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Fasturtec TLS Treatment / Prophylysis

NCT00651911
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
urate oxidase
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 29, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions
BPX-701, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FemBloc® Permanent Contraception - Early Pivotal Trial

NCT03433911
View directory record Official record
Conditions
Contraception
Interventions
FemBloc, Laparoscopic bilateral tubal sterilization
Device · Procedure
Lead sponsor
Femasys Inc.
Industry
Eligibility
21 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
12
States / cities
Chandler, Arizona • Stanford, California • Lake Worth, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects

NCT00426244
View directory record Official record
Conditions
Low Back Pain, Pregnancy
Interventions
Osteopathic Manipulative Treatment, Placebo Ultrasound
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

NCT02598934
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 29, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Retrospective Study to Evaluate the Effectiveness of the Ulthera System

NCT01519934
View directory record Official record
Conditions
Skin Laxity, Wrinkles
Interventions
Not listed
Lead sponsor
Ulthera, Inc
Industry
Eligibility
25 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 29, 2026, 5:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Not listed Not applicable Interventional

Trial of Methadone Maintenance Versus Methadone Detox in Jail

NCT01874964
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Methadone Maintenance, Linkage to methadone maintenance
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Black Health Identification Program (B-HIP)

NCT05129709
View directory record Official record
Conditions
Multiple Chronic Conditions, Family Members
Interventions
"My Health Priorities" Identification Program
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

NCT01878799
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
GS-7977/GS- 5885 FDC
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional

A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS

NCT00001999
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Globulin, Immune, Ganciclovir
Drug
Lead sponsor
American National Red Cross
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

NCT00021099
View directory record Official record
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 29, 2026, 5:48 PM EDT
Withdrawn Phase 3 Interventional

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

NCT00319332
View directory record Official record
Conditions
Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
Interventions
Ibritumomab Tiuxetan, Iodine I 131 Tositumomab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Buffalo, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 29, 2026, 5:48 PM EDT
Not yet recruiting Not applicable Interventional

Sleep MAPP in the Polytrauma/TBI System of Care

NCT07886398
View directory record Official record
Conditions
Insomnia Disorder, Mild Traumatic Brain Injury
Interventions
Sleep MAPP Care Pathway
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287
View directory record Official record
Conditions
Solid Tumor
Interventions
Decitabine, Cedazuridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Preservation of Joint Function Using Postoperative Continuous Passive Motion (CPM) A Pilot Study

NCT01420887
View directory record Official record
Conditions
Elbow Injury
Interventions
Continuous Passive Motion, Physical Therapy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Translation of Robotic Apparel for Alleviating Low Back Pain

NCT05736393
View directory record Official record
Conditions
Low Back Pain
Interventions
Back Exosuit
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs

NCT02609893
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
modified directly observed therapy (mDOT), unobserved dosing, Motivational Interviewing-based counseling
Other
Lead sponsor
Phillip Coffin, MD, MIA
Government
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 29, 2026, 5:48 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT05167721
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Autologous Mesenchymal Stem Cells, Placebo
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BFR Therapy Following DRF

NCT05396521
View directory record Official record
Conditions
Distal Radius Fracture
Interventions
Blood Flow Restriction, Standard of Care Physical Therapy
Other
Lead sponsor
Carilion Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Feasibility and Impact of Yoga in Obesity

NCT05031221
View directory record Official record
Conditions
Yoga, Obesity, Weight Loss
Interventions
Yoga + behavioral weight loss
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921
View directory record Official record
Conditions
Diabetic Neuropathies, Neuropathic Pain, Pain, Chronic
Interventions
Omnitram Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Anaheim, California • Cerritos, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 29, 2026, 5:48 PM EDT
Terminated Not applicable Interventional Results available

Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer

NCT03111914
View directory record Official record
Conditions
Dual Energy CT (DECT), Prostate Cancer
Interventions
Dual Energy Computed Tomography
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 29, 2026, 5:48 PM EDT